Department of Clinical Sciences at Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
Department of Obstetrics and Gynecology, Danderyd Hospital, Stockholm, Sweden.
Acta Obstet Gynecol Scand. 2022 Apr;101(4):424-430. doi: 10.1111/aogs.14331. Epub 2022 Feb 10.
In this open-label, randomized controlled, non-inferiority, multicenter study we aimed to study the risk of termination of pregnancy within 1 year postpartum, the safety profile and patient acceptability after early postpartum insertion of a hormonal intrauterine device (LNG-IUS, Mirena®) compared with standard placement 6-8 weeks postpartum.
April 2018 to January 2020 women with uncomplicated vaginal delivery at four urban birth centers in Sweden, were randomized to either early placement within 48 h after delivery (early group) or standard placement 6-8 weeks postpartum (standard group) of a hormonal intrauterine device. The main outcome measure was the proportion of terminations of pregnancies in each group during the first year after placement of the intrauterine device. Registration EudraCT database no. 2017-001945-29.
The study was prematurely stopped according to the protocol due to an expulsion rate >20% in the early group. No pregnancies occurred. Fifty-two women were randomized to early and 49 women to standard insertion. In the early group, 23/52 (44.2%) of the intrauterine devices were expelled. After expulsion, 10 women chose to have another hormonal intrauterine device placed but still significantly fewer women (39/52, 75%, p = 0.22) in the early group used the hormonal intrauterine device method at study completion. No expulsions occurred in the standard group, but 5/49 (10.2%) requested removal and 41/49 (83.7%, p = 0.22) had used the hormonal intrauterine device method continuously for 1 year.
Early hormonal intrauterine device insertion after vaginal delivery is associated with high expulsion rates. Despite this, a high continuation rate of the hormonal intrauterine device method is seen among women once choosing the method. In the light of high continuation rates, the advantages of early insertion could balance the risk of expulsion for well-informed women.
在这项开放标签、随机对照、非劣效性、多中心研究中,我们旨在研究产后 1 年内终止妊娠的风险、产后早期放置激素宫内节育器(LNG-IUS,Mirena®)的安全性概况和患者可接受性,与产后 6-8 周标准放置相比。
2018 年 4 月至 2020 年 1 月,在瑞典四个城市生育中心进行单纯阴道分娩的妇女,随机分为产后 48 小时内早期放置(早期组)或产后 6-8 周标准放置(标准组)激素宫内节育器。主要观察指标为每组放置宫内节育器后 1 年内终止妊娠的比例。在 EudraCT 数据库注册号 2017-001945-29。
根据方案,由于早期组的排出率>20%,该研究提前停止。没有发生妊娠。52 名妇女被随机分为早期组,49 名妇女被随机分为标准组。在早期组,52 名宫内节育器中有 23 名(44.2%)被排出。排出后,10 名妇女选择再次放置激素宫内节育器,但仍有更多的妇女(39/52,75%,p=0.22)选择使用激素宫内节育器法,在研究结束时,早期组。在标准组未发生排出,但 5/49(10.2%)要求取出,41/49(83.7%,p=0.22)持续使用激素宫内节育器法 1 年。
阴道分娩后早期放置激素宫内节育器与高排出率相关。尽管如此,一旦选择了该方法,仍有很高的激素宫内节育器方法的持续率。鉴于较高的持续率,对于知情的女性来说,早期放置的优势可能会平衡排出的风险。